Biofrontera AG

General Information
Business:

(Note: Public offering “Our ordinary shares are listed on the Frankfurt Stock Exchange under the symbol “B8F” since Oct. 3, 2006. On February 2, 2018, the closing price of our ordinary shares on the Frankfurt Stock Exchange was €6.21 ($7.70, based upon the noon buying rate of the Federal Reserve Bank of New York for the euro on January 26, 2018, which was €1.00 to $1.24.)

We are an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Our approved products focus on the treatment of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of basal cell carcinoma in the EU.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 125
Founded: 1997
Contact Information
Address Hemmelrather Weg 201, D-51377 Leverkusen, Germany
Phone Number 011 49 214 876 00
Web Address http://www.biofrontera.com
View Prospectus: Biofrontera AG
Financial Information
Market Cap
Revenues $12.3 mil (last 12 months)
Net Income $-19.3 mil (last 12 months)
IPO Profile
Symbol BFRA
Exchange NASDAQ
Shares (millions): 1.2
Price range $9.88 - $9.88
Est. $ Volume $12.0 mil
Manager / Joint Managers Benchmark
CO-Managers Dawson James Securities/ Lake Street Capital Markets
Expected To Trade: 2/14/2018
Status:
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change